Compare Efficacy of Oxytocin Administrations on Postpartum Uterine Contractility
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden
- Karolinska Institute, Danderyd hospital,Dept of Obstetrics and Gynecology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy, term pregnant female with a gestational age of 37-42 weeks (singleton)
- Undergoing a planned primary and uncomplicated caesarean section (CS) for their first born under regional anaesthesia
- Aged between 18 and 40 years (both inclusive)
- Ability to communicate well with the Investigator and to comply with the requirements of the entire study
- Willing to give informed consent in writing.
Exclusion Criteria:
- Being obese with BMI ≥35 before pregnancy
- History of, or existing thromboembolic, cardiovascular or cerebrovascular disorder
- History of cervical cancer
- History of severe infection of the uterus
- Previous surgery of the cervix or uterus or any other (previous) condition that could interfere with the measurement of uterine contractility
- Any clinically significant abnormality following review of medical history, laboratory result and physical examination at screening as judged by the Investigator
- Conditions or disorders that might affect the absorption, distribution, metabolism or excretion of any of the study medication
- Contraindications for oxytocin use
- Hypersensitivity to the active substances or to any of the excipients of the investigational product (test product or comparator drug)
- Present use or use within 30 days before the start of the study medication of one or more of the following medications: antihypertensive drugs, anti-coagulant therapy, medication that could affect myometrial contractility, sex steroids, prostaglandins and its analogues, inhalation anaesthetics, vasoconstrictors/sympathomimetics and caudal anaesthetics, vasopressin-like drugs
- Administration of any other investigational drug within 3 months before first dosing
- Tobacco use (smoking or snuffing), currently or within the last 6 months before screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Oxytocin intravenous
single dose of intravenous (IV) oxytocin
|
Oxytocin drug
|
|
Experimental: Oxytocin tablet
single dose of oxytocin tablet
|
Oxytocin drug
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Uterine contractility: area under the curve (AUC)
Time Frame: 3 hours
|
3 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OXB-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.